Checchi Capital Advisers LLC Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Checchi Capital Advisers LLC lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 673 shares of the biopharmaceutical company’s stock after selling 19 shares during the period. Checchi Capital Advisers LLC’s holdings in Regeneron Pharmaceuticals were worth $479,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. SteelPeak Wealth LLC lifted its stake in shares of Regeneron Pharmaceuticals by 1.5% in the 3rd quarter. SteelPeak Wealth LLC now owns 1,108 shares of the biopharmaceutical company’s stock valued at $1,165,000 after purchasing an additional 16 shares during the last quarter. Oak Harvest Investment Services grew its stake in Regeneron Pharmaceuticals by 25.6% during the 3rd quarter. Oak Harvest Investment Services now owns 2,779 shares of the biopharmaceutical company’s stock worth $2,921,000 after purchasing an additional 567 shares in the last quarter. Fairfield Financial Advisors LTD acquired a new stake in Regeneron Pharmaceuticals in the third quarter valued at approximately $37,000. LCM Capital Management Inc grew its stake in shares of Regeneron Pharmaceuticals by 4.6% during the third quarter. LCM Capital Management Inc now owns 543 shares of the biopharmaceutical company’s stock worth $571,000 after purchasing an additional 24 shares in the last quarter. Finally, Focus Financial Network Inc. boosted its position in shares of Regeneron Pharmaceuticals by 7.4% during the 3rd quarter. Focus Financial Network Inc. now owns 538 shares of the biopharmaceutical company’s stock worth $566,000 after acquiring an additional 37 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on REGN. Piper Sandler reduced their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research report on Monday, January 27th. Canaccord Genuity Group assumed coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. Oppenheimer cut their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Finally, TD Cowen reduced their target price on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Stock Down 0.6 %

Shares of NASDAQ REGN opened at $702.78 on Friday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $642.00 and a 12-month high of $1,211.20. The stock has a fifty day moving average price of $698.57 and a 200 day moving average price of $873.11. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The company has a market cap of $76.83 billion, a P/E ratio of 18.36, a P/E/G ratio of 2.34 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business’s revenue was up 10.3% on a year-over-year basis. During the same period last year, the business earned $11.86 EPS. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.50%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.